BioCryst Pharmaceuticals, Inc. $BCRX Stock Sold by Fisher Asset Management LLC

Fisher Asset Management LLC decreased its position in BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX – Free Report) by 6.0% in the third quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 2,448,598 shares of the biotechnology company’s stock after selling 155,429 shares during the quarter. Fisher Asset Management LLC’s holdings in BioCryst Pharmaceuticals were worth $20,397,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Other hedge funds also recently bought and sold shares of the company. Nykredit A S purchased a new stake in BioCryst Pharmaceuticals in the second quarter worth approximately $27,000. Winthrop Capital Management LLC bought a new position in BioCryst Pharmaceuticals during the third quarter valued at approximately $25,000. IFP Advisors Inc grew its position in BioCryst Pharmaceuticals by 2,515.3% during the second quarter. IFP Advisors Inc now owns 3,243 shares of the biotechnology company’s stock valued at $32,000 after acquiring an additional 3,119 shares during the last quarter. Allworth Financial LP purchased a new position in shares of BioCryst Pharmaceuticals during the second quarter worth approximately $52,000. Finally, Pallas Capital Advisors LLC purchased a new position in shares of BioCryst Pharmaceuticals during the second quarter worth approximately $101,000. Institutional investors own 85.88% of the company’s stock.

BioCryst Pharmaceuticals Stock Performance

NASDAQ BCRX opened at $7.61 on Monday. BioCryst Pharmaceuticals, Inc. has a 1-year low of $6.23 and a 1-year high of $11.22. The stock has a 50-day moving average of $8.23 and a 200-day moving average of $8.78. The firm has a market cap of $1.96 billion, a PE ratio of -5.36 and a beta of 0.55.

BioCryst Pharmaceuticals (NASDAQ:BCRX – Get Free Report) last issued its earnings results on Wednesday, November 4th. The biotechnology company reported $0.14 earnings per share for the quarter, beating the consensus estimate of $0.09 by $0.05. The company had revenue of $180.29 million during the quarter, compared to analysts’ expectations of $165.67 million. BioCryst Pharmaceuticals had a negative return on equity of 92.91% and a negative net margin of 37.40%. BioCryst Pharmaceuticals’s quarterly revenue was up 13.1% compared to the same quarter last year. During the same period in the prior year, the business posted $0.06 EPS. As a group, equities research analysts forecast that BioCryst Pharmaceuticals, Inc. will post -2.28 earnings per share for the current fiscal year.

Analyst Upgrades and Downgrades

BCRX has been the subject of a number of recent research reports. Wall Street Zen lowered shares of BioCryst Pharmaceuticals from a “strong-buy” rating to a “hold” rating in a report on Saturday, November 7th. Needham & Company LLC reaffirmed a “buy” rating and issued a $16.00 price objective on shares of BioCryst Pharmaceuticals in a research note on Tuesday, September 8th. Wedbush reduced their target price on shares of BioCryst Pharmaceuticals from $18.00 to $17.00 and set an “outperform” rating on the stock in a report on Thursday, November 5th. Royal Bank Of Canada cut shares of BioCryst Pharmaceuticals from an “outperform” rating to a “sector perform” rating and decreased their target price for the stock from $13.00 to $11.00 in a research report on Thursday, September 10th. Finally, Weiss Ratings cut shares of BioCryst Pharmaceuticals from a “hold (c)” rating to a “sell (d-)” rating in a research report on Tuesday, September 22nd. Six research analysts have rated the stock with a Buy rating, two have assigned a Hold rating and one has given a Sell rating to the company. According to data from MarketBeat, the company currently has an average rating of “Moderate Buy” and an average target price of $20.38.

View Our Latest Research Report on BCRX

About BioCryst Pharmaceuticals

(Free Report)

BioCryst Pharmaceuticals is a biotechnology company that discovers, develops and commercializes medicines for rare diseases. Founded in 1986, the company is headquartered in Durham, North Carolina, and focuses on small-molecule treatments. Its principal product is ORLADEYO (berotralstat), an oral medicine for preventing attacks of hereditary angioedema, a rare condition that causes episodes of swelling. BioCryst also develops medicines for rare diseases, including candidates targeting hereditary angioedema and complement-mediated disorders.

Featured Articles

Want to see what other hedge funds are holding BCRX? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX – Free Report).

Institutional Ownership by Quarter for BioCryst Pharmaceuticals (NASDAQ:BCRX)

Receive News & Ratings for BioCryst Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for BioCryst Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.